奥锐特药业股份有限公司关于部分高管减持股份计划公告

Core Viewpoint - The announcement details a share reduction plan by a senior executive of Aorite Pharmaceutical Co., Ltd. due to personal financial needs, involving a maximum reduction of 62,500 shares, which is 0.02% of the total share capital [2][3]. Group 1: Executive Shareholding Information - As of the announcement date, the total number of shares for Aorite Pharmaceutical is 406,195,234, with the executive Zhao Zhenping holding 250,000 shares, representing 0.06% of the total share capital [2]. Group 2: Reduction Plan Details - The executive plans to reduce shares through centralized bidding within three months after the announcement, starting 15 trading days later, with a maximum of 62,500 shares to be sold [3]. - The reduction will not exceed 25% of the executive's total shareholding, and any changes in share capital due to dividends or other corporate actions will adjust the reduction quantity accordingly [3]. Group 3: Other Relevant Information - The executive has no concerted actions with other shareholders and has made prior commitments regarding shareholding and reduction methods [4][6]. - The company will monitor the reduction plan and comply with relevant regulations, ensuring timely disclosure of any developments [9][17].